EQUILLIUM INC (EQ)

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023

EQ stock results show that Equillium beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Equillium (NASDAQ:EQ) just reported results for the fourth quarter of 2023.Equi...

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium to Host Analyst & Investor Day

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday morning!

Equillium approves $7.5M share buyback, stock jumps more than 30% after hours (NASDAQ:EQ)

Clinical-stage biotech Equillium (EQ) on Thursday said its board had approved a share buyback of up to $7.5M. Read more here.

Equillium Announces $7.5 Million Share Repurchase Program

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR